<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Eur. J. Cancer</journal-id><journal-title-group><journal-title>European Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0959-8049</issn><issn pub-type="epub">1879-0852</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7269953</article-id><article-id pub-id-type="publisher-id">S0959-8049(20)30303-8</article-id><article-id pub-id-type="doi">10.1016/j.ejca.2020.05.026</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Di Cosimo</surname><given-names>Serena</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Malfettone</surname><given-names>Andrea</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>Jos&#x000e9; M.</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Llombart-Cussac</surname><given-names>Antonio</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Miceli</surname><given-names>Rosalba</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Curigliano</surname><given-names>Giuseppe</given-names></name><xref rid="aff6" ref-type="aff">f</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Cort&#x000e9;s</surname><given-names>Javier</given-names></name><email>jacortes@vhio.net</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff8" ref-type="aff">h</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy</aff><aff id="aff2"><label>b</label>Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain</aff><aff id="aff3"><label>c</label>IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain</aff><aff id="aff4"><label>d</label>Hospital Arnau de Vilanova, Universidad Cat&#x000f3;lica de Valencia San Vicente M&#x000e1;rtir, Valencia, Spain</aff><aff id="aff5"><label>e</label>Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy</aff><aff id="aff6"><label>f</label>Istituto Europeo di Oncologia, IRCCS, Milano, Italy</aff><aff id="aff7"><label>g</label>University of Milano, School of Medicine, Milano, Italy</aff><aff id="aff8"><label>h</label>Vall D&#x000b4;Hebron Institute of Oncology (VHIO), Barcelona, Spain</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><italic>Corresponding author</italic>: IOB Institute of Oncology, Quironsalud Group Hospital Ruber Internacional, Calle de La Mas&#x000f3; 38, 28034, Madrid, Spain. <email>jacortes@vhio.net</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>4</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>8</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>4</day><month>6</month><year>2020</year></pub-date><volume>135</volume><fpage>62</fpage><lpage>65</lpage><history><date date-type="received"><day>23</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets&#x000a0;and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Patients with severe coronavirus disease 2019 (COVID-19) present with lymphocytopenia and T-cell exhaustion.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Persistent stimulation by severe acute respiratory syndrome coronavirus 2 leads to the inhibition of the immune system.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Immune blockade in patients with cancer supports host protective immunity.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Immune checkpoint inhibitors safely restore immunocompetence in sepsis and viral infections.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0030">Immunostimulants should be considered as the first-line option in severe COVID-19.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Cytokine storm</kwd><kwd>Anti&#x02013;PD-1</kwd><kwd>Anti&#x02013;IL-6R</kwd><kwd>Pembrolizumab</kwd><kwd>Tocilizumab</kwd></kwd-group></article-meta></front><body><p id="p0035">Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a positive-sense RNA betacoronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. Elevated concentrations of proinflammatory cytokines and chemokines including interleukin (IL)-2, IL-6, interferon gamma&#x02013;induced protein 10, macrophage inflammatory protein alpha, monocyte chemotactic protein 1 and tumour necrosis factor-alpha (TNF-&#x003b1;) [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>] suggest that a cytokine release syndrome may play a major role in the pathology of COVID-19.</p><p id="p0040">Higher mortality has been linked to elderly subjects and those with comorbidities including pulmonary disease, cardiac disease, kidney disease, diabetes, hypertension and cancer [<xref rid="bib3" ref-type="bibr">3</xref>]. Whether cancer <italic>per se</italic> increases the risk of SARS-CoV-2 infection and its complications or rather cancer-associated comorbidities and treatment remains to be clarified. A recent study showed that patients with cancer undergoing chemotherapy or surgery in the past month have an increased risk of severe complications compared with those not receiving recent treatments [<xref rid="bib4" ref-type="bibr">4</xref>]. This risk seemed higher in the presence of additional chronic medical conditions, which is consistent with other recent reports [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. Curiously, none of the patients in this study received anticancer immunotherapy including treatment with immune checkpoint inhibitors (ICIs), which are extensively used to treat many cancers. Given the limited number of cases analysed, these findings could simply be due to chance; however, it also adds to other evidence suggesting that ICIs are protective rather than harmful in patients with COVID-19. While chemotherapies are indeed known to exert a systemic immunosuppression along with a myelosuppressive state by lowering the complete blood count and/or impairing the immune regulatory response even in the face of a normal blood test, this seems not to be the case for ICIs. On the contrary, they restore cellular immunocompetence [<xref rid="bib6" ref-type="bibr">6</xref>].</p><p id="p0045">The immune checkpoint pathway is an endogenous component of the immune system that is responsible for coordinating the physiological immune response, maintaining self-tolerance and protecting tissues from damage. Several models have shown that blocking programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) can prevent T-cell death, regulate cytokine production&#x000a0;and reduce organ dysfunctions. T cells play a vital role in viral clearance, with CD8<sup>+</sup> cytotoxic T cells (CTLs) capable of secreting an array of molecules such as perforin, granzymes&#x000a0;and interferon gamma to eradicate viruses from the host. At the same time, CD4<sup>+</sup> helper T cells (Ths) can assist CTLs and B cells and enhance their ability to clear pathogens. However, persistent stimulation by the virus may induce T-cell exhaustion, leading to a loss of cytokine production capability and reduced functions [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib8" ref-type="bibr">8</xref>]. Many factors are involved in this process, and negative costimulatory molecules including immune checkpoints are key elements.</p><p id="p0050">There is increasing recognition that a state of impaired host immunity accompanied by a significant cell degeneration in secondary lymphoid tissues follows the initial hyperinflammatory phase of COVID-19. First, critically ill high-risk patients with COVID-19 often present with lymphocytopenia: A fall in the total lymphocyte number to 0.6&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>/mL is associated with a mortality rate of 75% [<xref rid="bib2" ref-type="bibr">2</xref>]. Second, patients with COVID-19 have high levels of serum IL-6, IL-10 and TNF-&#x003b1; and express increased levels of exhaustion markers PD-1 and T-cell immunoglobulin mucin-3 on the surface of their peripheral T cells, which in turn impair T-cell effector functions and prevent functional memory [<xref rid="bib9" ref-type="bibr">9</xref>]. Finally, compared with cases of pneumonia not caused by SARS-CoV-2, patients with COVID-19 have decreased B cell and Th counts but a comparable number of the main cytokine storm (CS) players including monocytes, neutrophils and natural killer cells [<xref rid="bib10" ref-type="bibr">10</xref>]. These latest data suggest that viral damage is direct rather than inflammatory driven and strongly supports the use of immune-activating drugs that have been little considered to date for fear of exacerbating the inflammatory reaction and causing a CS.</p><p id="p0055">Among immune-activating drugs, ICIs have been recently tested beyond cancer treatment for their potential to restore immunocompetence in the context of sepsis and influenza infection. A recent phase Ib trial reported that in patients with systemic sepsis, the anti&#x02013;PD-1 monoclonal antibody nivolumab can restore lymphocyte count and function with no concern on the CS, i.e.&#x000a0;levels of IL-6, IL-8&#x000a0;and TNF-&#x003b1; are unaffected [<xref rid="bib11" ref-type="bibr">11</xref>]. These findings were consistent with those of the anti&#x02013;PD-L1 monoclonal antibody BMS-936559 in patients with sepsis-induced immunosuppression [<xref rid="bib12" ref-type="bibr">12</xref>]. Another intervention aimed at testing the safety of ICIs was influenza vaccination in patients with cancer treated with anti&#x02013;PD-1/anti&#x02013;PD-L1 antibodies. Several studies reported no increase of incidence or severity of immune-related adverse events [<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref>], and as an additional finding, a lower overall rate of influenza among vaccinated patients when compared with rates of laboratory-confirmed influenza has been reported [<xref rid="bib14" ref-type="bibr">14</xref>]. Other data show that ICI-induced pneumonitis is a very rare phenomenon, with 2.5&#x02013;5% with anti&#x02013;PD-1/anti&#x02013;PD-L1 single-agent therapy to 7&#x02013;10% with dual checkpoint blockade, and most patients experienced clinically significant, new or worsening immune-related adverse events after the first 6 months of treatment [<xref rid="bib15" ref-type="bibr">15</xref>]. These data suggest that ICIs enhance T-cell response to viral antigens without triggering unintended immune consequences including the CS and autoimmunity.</p><p id="p0060">Currently, there are no finally verified data and no antiviral drugs licensed by the US Food and Drug Administration and European Medicines Agency for treating patients with COVID-19 or for managing their complications. Since its first outbreak in China, COVID-19 was empirically treated with antiviral and respiratory supportive therapies mainly agents already used in prior SARS epidemics. Thus, this provides an opportunity for the research community to better outline the value of immune-modulating agents in the treatment of COVID-19. Current evidence revealed that a timely anti-inflammation treatment is of pivotal importance in avoiding exacerbation and preventing further injury in severe SARS-CoV-2&#x02013;induced pneumonia. Although the use of some of them is still controversial, a plethora of anti-inflammatory agents have been proposed to alleviate the systemic CS. Based on the promising results from an open-label study in 21 patients with severe and critical COVID-19 [<xref rid="bib16" ref-type="bibr">16</xref>], tocilizumab&#x02014;a human monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (IL-6Rs)&#x02014;is currently being investigated to address cytokine release syndrome in patients with severe ARDS, which includes randomised, controlled trials (ChiCTR2000029765; NCT04320615) and single-arm trials (ChiCTR2000030796; NCT04317092). These studies must be considered alongside two trials assessing the safety and therapeutic efficacy of anti&#x02013;PD-1 inhibitors in patients with similar eligibility criteria (NCT04268537; NCT04333914).</p><p id="p0065">Regardless of the shortcomings reported in patients receiving single-agent tocilizumab, it is likely that more effective treatments targeting both overexuberant inflammation and exhausted T cells require the combination of two classes of agents because they work through in a different and complementary mechanism. PD-1 expression likely increases to prevent an uncontrolled inflammatory cascade [<xref rid="bib17" ref-type="bibr">17</xref>]. Therefore, the use of anti&#x02013;PD-1 treatment would produce satisfactory therapeutic effects in combination with an anti&#x02013;IL-6R. This approach requires caution. Indeed, in the early phase of viral infection, the PD-1/PD-L1 axis is also involved in the physiological process of T-cell maturation, implying that PD-1 negatively regulates the terminal differentiation of naive CTLs into effector T cells. Thus, the blockade of the PD-1 pathway adjusts the strength and quality of cytotoxic cell attack to accelerate virus clearance with minimal collateral tissue damage [<xref rid="bib17" ref-type="bibr">17</xref>]. However, in a later phase, the blockade of the coinhibitory receptor PD-1 can release the brake in exhausted T cells that in turn increases the antiviral T-cell responses [<xref rid="bib18" ref-type="bibr">18</xref>].</p><p id="p0070">Most importantly, the CD8<sup>+</sup> T-cell immunosurveillance of viruses is dependent on human leucocyte antigen class I (HLA-I) molecules that are expressed on the surface of all nucleated cells. Genetic differences in <italic>HLA</italic> alleles have been recently recognised to confer differential viral susceptibility and severity of COVID-19 [<xref rid="bib19" ref-type="bibr">19</xref>]. Data validated in two independent cohorts of patients with cancer receiving ICIs revealed that heterozygous <italic>HLA-I</italic> genotypes were associated with better survival than homozygosity for one or more <italic>HLA-I</italic> genes, and treatment efficacy was diminished by loss of <italic>HLA-I</italic> heterozygosity [<xref rid="bib20" ref-type="bibr">20</xref>]. These findings highlight that genetic variability in the immune system may affect susceptibility to (and severity of) SARS-CoV-2; therefore, strategies to boost immune responses at this stage are certainly important for individuals particularly vulnerable to COVID-19.</p><p id="p0075">We believe that there is sufficient evidence to support clinical trials combining IL-6R antagonists with PD-1 inhibitors to improve outcomes in patients with COVID-19. We propose that an earlier intervention with anti&#x02013;PD-1 therapy will minimise the need for intensive care support.</p><sec id="sec1"><title>Author contributions</title><p id="p0080">All authors listed have made a substantial, direct and intellectual contribution to the work and approved it for publication.</p></sec><sec sec-type="COI-statement"><title>Conflict of interest statement</title><p id="p0085">S.D.C. reports fees for medical education from <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source> and Pierre Fabre and is a recipient of the IG20774 of Fondazione <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100005010</institution-id><institution>AIRC</institution></institution-wrap></funding-source>. J.M.P.-G. is a consultant/advisory board member for Roche and Lilly and reports travel and accommodation fees paid by Roche. A.L.-C. plays a leadership role for <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003769</institution-id><institution>Eisai</institution></institution-wrap></funding-source>, <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006436</institution-id><institution>Celgene</institution></institution-wrap></funding-source>, <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source>, <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source> and MSD; reports stock or other ownership in MedSIR and Initia-Research; is a consultant/advisory board member for <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs13"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, <funding-source id="gs15"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source>, Pierre Fabre, <funding-source id="gs16"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008067</institution-id><institution>Genomic Health</institution></institution-wrap></funding-source> and GSK; is on the speakers' bureau of and reports honoraria from <funding-source id="gs17"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, AstraZeneca and MSD; reports research funding to the institution from <funding-source id="gs18"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, Foundation Medicine, Pierre Fabre and Agendia and reports travel and accommodation fees paid by <funding-source id="gs19"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs20"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs21"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source>, <funding-source id="gs22"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source> and <funding-source id="gs23"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source>. G.C. is a consultant/advisory board member for <funding-source id="gs24"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs25"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010293</institution-id><institution>Seattle Genetics</institution></institution-wrap></funding-source>, Daiichi Sankyo, <funding-source id="gs26"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs27"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100011725</institution-id><institution>Servier</institution></institution-wrap></funding-source>, <funding-source id="gs28"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source> Sharp &#x00026; Dohme, <funding-source id="gs29">GSK</funding-source>, Bioasis and Clovis Oncology; reports honoraria from <funding-source id="gs30"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs31"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source>, <funding-source id="gs32"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, <funding-source id="gs33"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004358</institution-id><institution>Samsung</institution></institution-wrap></funding-source>
<funding-source id="gs34"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs35"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source> Sharp &#x00026; Dohme and Daiichi Sankyo and reports research funding to the institution from <funding-source id="gs36"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source>. J.C. reports stock or other ownership in MedSIR; is a consultant/advisory board member for <funding-source id="gs37"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs38"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006436</institution-id><institution>Celgene</institution></institution-wrap></funding-source>, Cellestia, <funding-source id="gs39"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source>, Biothera Pharmaceuticals, Merus, <funding-source id="gs40"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010293</institution-id><institution>Seattle Genetics</institution></institution-wrap></funding-source>, Daiichi Sankyo, Erytech, Athenex, Polyphor, <funding-source id="gs41"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs42"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100011725</institution-id><institution>Servier</institution></institution-wrap></funding-source>, <funding-source id="gs43"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source> Sharp &#x00026; Dohme, <funding-source id="gs44">GSK</funding-source>, Leuko, Bioasis and Clovis Oncology; reports honoraria from <funding-source id="gs45"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs46"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source>, <funding-source id="gs47"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006436</institution-id><institution>Celgene</institution></institution-wrap></funding-source>, <funding-source id="gs48"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003769</institution-id><institution>Eisai</institution></institution-wrap></funding-source>, <funding-source id="gs49"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, <funding-source id="gs50"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004358</institution-id><institution>Samsung</institution></institution-wrap></funding-source> Bioepis, <funding-source id="gs51"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs52"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source> Sharp &#x00026; Dohme and Daiichi Sankyo and reports research funding to the institution from <funding-source id="gs53"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs54"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006413</institution-id><institution>Ariad</institution></institution-wrap></funding-source> Pharmaceuticals, <funding-source id="gs55"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source>, <funding-source id="gs56"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009431</institution-id><institution>Baxalta</institution></institution-wrap></funding-source> GmbH/<funding-source id="gs57"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100011725</institution-id><institution>Servier</institution></institution-wrap></funding-source> Affaires, <funding-source id="gs58"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004326</institution-id><institution>Bayer</institution></institution-wrap></funding-source> Healthcare, <funding-source id="gs59"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003769</institution-id><institution>Eisai</institution></institution-wrap></funding-source>, F. Hoffmann-La Roche, Guardant Health, Merck Sharp &#x00026; Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London. A.M. and R.M. declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><issue>10229</issue><year>2020</year><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>An</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name></person-group><article-title>Comorbidities and multi-organ injuries in the treatment of COVID-19</article-title><source>Lancet</source><volume>395</volume><issue>10228</issue><year>2020</year><fpage>e52</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30558-4</pub-id><pub-id pub-id-type="pmid">32171074</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Guan</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>K.</given-names></name></person-group><article-title>Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China</article-title><source>Lancet Oncol</source><volume>21</volume><issue>3</issue><year>2020</year><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30096-6</pub-id><pub-id pub-id-type="pmid">32066541</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Ouyang</surname><given-names>W.</given-names></name><name><surname>Chua</surname><given-names>M.L.K.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name></person-group><article-title>SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China</article-title><source>JAMA Oncol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.0980</pub-id><comment>Published online March 25</comment></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Bersanelli</surname><given-names>M.</given-names></name><name><surname>Scala</surname><given-names>S.</given-names></name><name><surname>Affanni</surname><given-names>P.</given-names></name><name><surname>Veronesi</surname><given-names>L.</given-names></name><name><surname>Colucci</surname><given-names>M.E.</given-names></name><name><surname>Banna</surname><given-names>G.L.</given-names></name></person-group><article-title>Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients</article-title><source>Immunotherapy</source><volume>12</volume><issue>2</issue><year>2020</year><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.2217/imt-2019-0200</pub-id><pub-id pub-id-type="pmid">32046555</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="book" id="sref7"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H.-Y.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>C.-X.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>X.-C.</given-names></name><name><surname>Yang</surname><given-names>X.-P.</given-names></name></person-group><chapter-title>Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. <italic>Cellular &#x00026; Molecular Immunology</italic></chapter-title><year>2020</year><fpage>1</fpage><lpage>3</lpage><comment>Published online March 17</comment></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="book" id="sref8"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name></person-group><chapter-title>Functional exhaustion of antiviral lymphocytes in COVID-19 patients. <italic>Cellular &#x00026; Molecular Immunology</italic></chapter-title><year>2020</year><fpage>1</fpage><lpage>3</lpage><comment>Published online March 19</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Tan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ning</surname><given-names>L.</given-names></name></person-group><article-title>Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.18.20024364</pub-id><comment>2020.02.18.20024364</comment></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="book" id="sref10"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Ying</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name></person-group><chapter-title>Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury</chapter-title><year>2020</year><publisher-name>Infectious Diseases (except HIV/AIDS)</publisher-name></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>R.S.</given-names></name><name><surname>Colston</surname><given-names>E.</given-names></name><name><surname>Yende</surname><given-names>S.</given-names></name><name><surname>Crouser</surname><given-names>E.D.</given-names></name><name><surname>Martin</surname><given-names>G.S.</given-names></name><name><surname>Albertson</surname><given-names>T.</given-names></name></person-group><article-title>Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab</article-title><source>Intensive Care Med</source><volume>45</volume><issue>10</issue><year>2019</year><fpage>1360</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1007/s00134-019-05704-z</pub-id><pub-id pub-id-type="pmid">31576433</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>R.</given-names></name><name><surname>Colston</surname><given-names>E.</given-names></name><name><surname>Yende</surname><given-names>S.</given-names></name><name><surname>Angus</surname><given-names>D.</given-names></name><name><surname>Moldawer</surname><given-names>L.</given-names></name><name><surname>Crouser</surname><given-names>E.</given-names></name></person-group><article-title>Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)&#x02217;</article-title><source>Crit Care Med</source><volume>47</volume><issue>5</issue><year>2019</year><fpage>632</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000003685</pub-id><pub-id pub-id-type="pmid">30747773</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Bayle</surname><given-names>A.</given-names></name><name><surname>Khettab</surname><given-names>M.</given-names></name><name><surname>Lucibello</surname><given-names>F.</given-names></name><name><surname>Chamseddine</surname><given-names>A.N.</given-names></name><name><surname>Goldschmidt</surname><given-names>V.</given-names></name><name><surname>Perret</surname><given-names>A.</given-names></name></person-group><article-title>Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1</article-title><source>Ann Oncol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.annonc.2020.03.290</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>C.R.</given-names></name><name><surname>Park</surname><given-names>V.J.</given-names></name><name><surname>Cohen</surname><given-names>B.</given-names></name><name><surname>Postow</surname><given-names>M.A.</given-names></name><name><surname>Wolchok</surname><given-names>J.D.</given-names></name><name><surname>Kamboj</surname><given-names>M.</given-names></name></person-group><article-title>Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors</article-title><source>Clin Infect Dis</source><volume>70</volume><issue>2</issue><year>2020</year><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz202</pub-id><pub-id pub-id-type="pmid">30874791</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Fu</surname><given-names>B.</given-names></name></person-group><article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title><source>China</source><volume>117</volume><year>2020</year><fpage>10970</fpage><lpage>10975</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005615117</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>E.</given-names></name><name><surname>Araki</surname><given-names>K.</given-names></name><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Riley</surname><given-names>J.L.</given-names></name><name><surname>Cheung</surname><given-names>J.</given-names></name></person-group><article-title>Role of PD-1 during effector CD8 T cell differentiation</article-title><source>Proc Natl&#x000a0;Acad Sci USA</source><volume>115</volume><issue>18</issue><year>2018</year><fpage>4749</fpage><lpage>4754</lpage><pub-id pub-id-type="doi">10.1073/pnas.1718217115</pub-id><pub-id pub-id-type="pmid">29654146</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Billerbeck</surname><given-names>E.</given-names></name><name><surname>Wolfisberg</surname><given-names>R.</given-names></name><name><surname>Fahn&#x000f8;e</surname><given-names>U.</given-names></name><name><surname>Xiao</surname><given-names>J.W.</given-names></name><name><surname>Quirk</surname><given-names>C.</given-names></name><name><surname>Luna</surname><given-names>J.M.</given-names></name></person-group><article-title>Mouse models of acute and chronic hepacivirus infection</article-title><source>Science</source><volume>357</volume><issue>6347</issue><year>2017</year><fpage>204</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1126/science.aal1962</pub-id><pub-id pub-id-type="pmid">28706073</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>A.</given-names></name><name><surname>David</surname><given-names>J.K.</given-names></name><name><surname>Maden</surname><given-names>S.K.</given-names></name><name><surname>Wood</surname><given-names>M.A.</given-names></name><name><surname>Weeder</surname><given-names>B.R.</given-names></name><name><surname>Nellore</surname><given-names>A.</given-names></name></person-group><article-title>Human leukocyte antigen susceptibility map for SARS-CoV-2</article-title><source>J Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1128/JVI.00510-20</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Chowell</surname><given-names>D.</given-names></name><name><surname>Morris</surname><given-names>L.G.T.</given-names></name><name><surname>Grigg</surname><given-names>C.M.</given-names></name><name><surname>Weber</surname><given-names>J.K.</given-names></name><name><surname>Samstein</surname><given-names>R.M.</given-names></name><name><surname>Makarov</surname><given-names>V.</given-names></name></person-group><article-title>Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy</article-title><source>Science</source><volume>359</volume><issue>6375</issue><year>2018</year><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1126/science.aao4572</pub-id><pub-id pub-id-type="pmid">29217585</pub-id></element-citation></ref></ref-list></back></article>